| Favipiravir |
2019-nCoV; influenza |
Inhibits RdRp |
• Approved for influenza in Japan |
| • Randomized trial for 2019-nCoV |
| (ChiCTR2000029544, ChiCTR2000029600) |
| Ribavirin |
2019-nCoV, MERS-CoV, SARS-CoV, RSV, HCV |
Inhibits viral RNA synthesis and mRNA capping |
• Approved for HCV and RSV |
| • Randomized trial for 2019-nCoV in combination a pegylated interferon (ChiCTR2000029387) |
| • Randomized trial for SARS (NCT00578825) |
| Penciclovir |
2019-nCoV |
Inhibits RdRp |
Approved for HSV |
| Remdesivir (GS-5734) |
2019-nCoV, MERS-CoV, SARS-CoV |
Terminates the non-obligate chain |
• Phase III for 2019-nCoV (NCT04252664, NCT04257656) |
| • Phase I for Ebola (NCT03719586) |
| Galidesivir (BCX4430) |
Broad-spectrum (e.g. SARS-CoV, MERS-CoV, IAV) |
Inhibits viral RNA polymerase function by terminating non-obligate RNA chain |
• Phase I for yellow fever (NCT03891420) |
| • Phase I for Marburg virus (NCT03800173) |
| 6′-Fluorinated-aristeromycin analogues |
Broad-spectrum (e.g. CoV, ZIKV, CHIKV) |
Inhibits the activity of RdRp and host cell S-adenosyl-l-homocysteine hydrolase |
Preclinical |
| Acyclovir fleximer analogues |
HCoV-NL63, MERS-CoV |
Doubly flexible nucleoside analogues inhibit RdRp |
Preclinical |
